IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: IL1RAP has been identified previously as a putative therapeutic stem cell-specific target in CML[34], as well as in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, with high expression correlating with poor overall survival in AML[35].